HeartBeam aligned with the FDA on a 510k pathway, plans a pivotal study beginning in 2027, reported Q3 2026 operating cash use of $2.6 million, and had pro forma cash of approximately $10.1 million.
BEAT · HeartBeam, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current business plan assumptions and expected cash burn rate, the Company believes that the existing cash is insufficient to fund operations for the next twelve months following the issuance of these financial statements. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.”View the 10-Q filed Nov 12, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 49%
- Last earnings
- Nov 12, 2026
- Latest filing
- 10-Q · Nov 12
- Price history
- Nov 2021 to Nov 2026
Up next
Latest documents
HeartBeam, Inc. received FDA Breakthrough Device Designation for heart attack assessment on October 5, 2026. ALIGN-ACS showed 81.8% specificity versus 71.4% for 12-lead ECG; Nasdaq compliance is due by December 28, 2026, and cash is insufficient for twelve months.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BEAT
this stock
HeartBeam, Inc.
|
$19.56M | -87.1% | — | — | 3.6% |
|
VEEV
Veeva Systems Inc
|
$42.57B | +17.8% | +28.1% | 43.0 | 2.4% |
|
PMDIY
Pro Medicus Ltd.
|
$14.81B | -14.6% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$12.74B | +70.9% | +28.2% | 34.8 | 5.8% |
|
TEM
Tempus AI, Inc.
|
$10.87B | +0.9% | +83.4% | — | 13.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 13.7%
- Net QoQ
- -23.6K sh
- Top holder
- VANGUARD CAPITAL MANAGEME…
- Filed
- Nov 12, 2026
- This year
- 16
HeartBeam, Inc. received FDA Breakthrough Device Designation for heart attack assessment on October 5, 2026. ALIGN-ACS showed 81.8% specificity versus 71.4% for 12-lead ECG; Nasdaq compliance is due by December 28, 2026, and cash is insufficient for twelve months.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BEAT | -23.5% | -22.4% | -65.1% | -43.8% | -87.1% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -18.0% | -16.1% | -59.4% | -38.6% | -92.1% |